证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 2025 年上半年度，公司采取降本增效措施，各项费用支出都在下降， 但受部分血透耗材产品集采降价的 影响，使得公司营业收入和产品利润 有一定幅度下降，同时公司银行存款利息利率下降使得利息收入相应减 少，以及美元兑人民币的汇率波动导致美元存款汇兑损失增加，以上原因 使得归属于上市公司股东的净利润增加较少。 2、公司监护类产品研发方向及动向？ 编号：20250901 投资者关系活 动类别 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他 时间 2025 年 9 月 4 日、2025 年 9 月 11 日 地点 深圳 参与单位名称 天风证券 周海涛 天大集团 张伟生 信达证券 曹佳琳 红土创新基金 杨皓童 华西基金 刘佳妍 远东宏信 付东杰 上市公司接待 人员姓名 董事会秘书 杨永兴 证券事务专员 钟欣昊 投资者关系活 动主要内容介 绍 公司介绍环节： 宝莱特成立于 1993 年，主营业务为医疗器械产品的研发、生产、销 售。公司作为中国最早一批研发制造医疗监护仪的民族企业，是国家发改 委 ...

Core Viewpoint - Guangdong Baolait Medical Technology Co., Ltd. recently engaged in in-depth discussions with three institutions regarding its business, performance, and new products [1] Group 1: Company Overview - Baolait has been focused on the research, production, and sales of medical devices since its establishment in 1993, being one of the earliest domestic manufacturers of medical monitors [3] - The company has received several accolades, including being recognized as a "National Multi-parameter Monitor Industrialization Base" and a "National Manufacturing Single Champion Enterprise" [3] - Its monitoring equipment is utilized in thousands of medical institutions, with a diverse product range in life information and support, as well as a comprehensive layout in the renal medical field [3] Group 2: Performance Summary - In the first half of 2025, Baolait reported an operating income of 523.44 million yuan, a year-on-year decrease of 2.43%, while net profit reached 1.31 million yuan, a significant increase of 152.22% [4] - Total assets amounted to 2.41 billion yuan, down 3.66% from the beginning of the period, and shareholders' equity was 1.22 billion yuan, up 0.25% [4] - The health monitoring segment saw revenues of 111.95 million yuan, down 16.01%, while the blood purification segment reported revenues of 405.70 million yuan, an increase of 1.79% [4] Group 3: New Products and Market Strategy - Baolait has launched new products such as the peritoneal dialysis machine and showcased the visual laryngoscope and enteral nutrition pump at CMEF in the first half of 2025 [4] - The "old-for-new" policy is expected to boost demand for monitoring devices, particularly benefiting mid-to-high-end products, while also facilitating equipment upgrades in the blood purification business [4] - The company has begun expanding its overseas sales of blood purification products, with overseas revenue growing by 121.29% in the first half of 2025 [4] Group 4: Future Focus - In 2025, Baolait aims to concentrate on its two main businesses, leveraging opportunities in new medical infrastructure, and developing high-margin intelligent IoT products [4] - The company plans to optimize its blood purification consumables supply chain and operational efficiency to enhance product penetration [4]